drugset / Trial / NCT03046953
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refractory to or has relapsed following initial treatment.
Timeline
- Start
- 2017-12-08
- Primary completion
- 2020-07-31
- Completion
- 2021-07-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 10 mg/kg | Intravenous |